New Proteon Logo - full color RGB.jpg
Proteon Therapeutics Receives FDA Breakthrough Therapy Designation for Vonapanitase
May 10, 2017 07:30 ET | Proteon Therapeutics, Inc.
WALTHAM, Mass., May 10, 2017 (GLOBE NEWSWIRE) -- Proteon Therapeutics, Inc. (Nasdaq:PRTO), a company developing novel, first-in-class therapeutics to address the medical needs of patients with...
New Proteon Logo - full color RGB.jpg
Proteon Therapeutics Announces Increase to Enrollment of Ongoing Phase 3 PATENCY-2 Clinical Trial
May 02, 2017 16:40 ET | Proteon Therapeutics, Inc.
WALTHAM, Mass., May 02, 2017 (GLOBE NEWSWIRE) -- Proteon Therapeutics Inc. (Nasdaq:PRTO), a company developing novel, first-in-class therapeutics to address the medical needs of patients with...
New Proteon Logo - full color RGB.jpg
Proteon Therapeutics to Present at the Deutsche Bank 42nd Annual Health Care Conference May 4th
May 01, 2017 08:00 ET | Proteon Therapeutics, Inc.
WALTHAM, Mass., May 01, 2017 (GLOBE NEWSWIRE) -- Proteon Therapeutics Inc. (Nasdaq:PRTO), a company developing novel, first-in-class therapeutics to address the medical needs of patients with kidney...
New Proteon Logo - full color RGB.jpg
Proteon Therapeutics to Present at the Oppenheimer 27th Annual Healthcare Conference March 22nd
March 17, 2017 07:55 ET | Proteon Therapeutics, Inc.
WALTHAM, Mass., March 17, 2017 (GLOBE NEWSWIRE) -- Proteon Therapeutics Inc. (Nasdaq:PRTO), a company developing novel, first-in-class therapeutics to address the medical needs of patients with...
New Proteon Logo - full color RGB.jpg
Proteon Therapeutics Announces Full-Year 2016 Financial Results and Changes to the Ongoing Phase 3 PATENCY-2 Clinical Trial
March 16, 2017 07:15 ET | Proteon Therapeutics, Inc.
- Efficacy endpoints reordered and co-primary endpoints established -- Ongoing trial, if successful, expected to serve as single pivotal study for BLA submission - - Conference Call Scheduled for...
New Proteon Logo - full color RGB.jpg
Proteon Therapeutics Announces Two Presentations at the American Society of Diagnostic and Interventional Nephrology Meeting  
February 06, 2017 17:00 ET | Proteon Therapeutics, Inc.
Review results of PATENCY-1, the Phase 3 trial of investigational vonapanitase Data on impact of fistula outcomes on Medicare costs WALTHAM, Mass., Feb. 06, 2017 (GLOBE NEWSWIRE) -- Proteon...
New Proteon Logo - full color RGB.jpg
Proteon Therapeutics Announces Top-Line Data from Phase 3 PATENCY-1 Clinical Trial of Investigational Vonapanitase in Patients with CKD
December 13, 2016 07:00 ET | Proteon Therapeutics, Inc.
- Trial Did Not Meet Primary Efficacy Endpoint - - Important Secondary and Tertiary Endpoint Data and Enrollment in Second Phase 3 Ongoing - - Conference Call Scheduled for 8:30 AM ET - WALTHAM,...
New Proteon Logo - full color RGB.jpg
Proteon Therapeutics to Participate in Two Upcoming Investor Conferences
November 09, 2016 16:35 ET | Proteon Therapeutics, Inc.
WALTHAM, Mass., Nov. 09, 2016 (GLOBE NEWSWIRE) -- Proteon Therapeutics, Inc. (Nasdaq:PRTO), a company developing novel, first-in-class therapeutics to address the medical needs of patients with...
New Proteon Logo - full color RGB.jpg
Proteon Therapeutics Announces Third Quarter 2016 Financial Results
November 07, 2016 08:00 ET | Proteon Therapeutics, Inc.
WALTHAM, Mass., Nov. 07, 2016 (GLOBE NEWSWIRE) -- Proteon Therapeutics, Inc. (Nasdaq:PRTO), a company developing novel, first-in-class therapeutics to address the medical needs of patients with...
New Proteon Logo - full color RGB.jpg
Proteon Therapeutics Appoints Paul Hastings Chairman of Its Board of Directors
October 20, 2016 08:00 ET | Proteon Therapeutics, Inc.
WALTHAM, Mass., Oct. 20, 2016 (GLOBE NEWSWIRE) -- Proteon Therapeutics Inc. (Nasdaq:PRTO), a company developing novel, first-in-class therapeutics to address the medical needs of patients with...